CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
![CRISPR Therapeutics logo](/files/LOGO/1674416-CRSP.png)
Company profile
Ticker
CRSP
Exchange
Website
CEO
Samarth Kulkarni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
CRISPR Therapeutics, Inc. • TRACR Hematology Ltd • CTX Financing GmbH • CTX Securities Corporation ...
CRSP stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
3 Jun 24
8-K
Departure of Directors or Certain Officers
23 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
8 May 24
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
PRE 14A
Preliminary proxy
27 Mar 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 718.94 mm | 718.94 mm | 718.94 mm | 718.94 mm | 718.94 mm | 718.94 mm |
Cash burn (monthly) | (no burn) | (no burn) | 46.86 mm | 23.22 mm | (no burn) | 13.29 mm |
Cash used (since last report) | n/a | n/a | 181.18 mm | 89.77 mm | n/a | 51.36 mm |
Cash remaining | n/a | n/a | 537.76 mm | 629.17 mm | n/a | 667.58 mm |
Runway (months of cash) | n/a | n/a | 11.5 | 27.1 | n/a | 50.2 |
Institutional ownership, Q1 2024
85.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 467 |
Opened positions | 147 |
Closed positions | 62 |
Increased positions | 122 |
Reduced positions | 106 |
13F shares | Current |
---|---|
Total value | 3.59 tn |
Total shares | 72.83 mm |
Total puts | 2.47 mm |
Total calls | 2.91 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 8.16 mm | $555.98 bn |
Capital International Investors | 7.84 mm | $534.17 bn |
VRTX Vertex Pharmaceuticals | 5.38 mm | $353.37 mm |
GSK GSK | 3.31 mm | $278.46 mm |
CMTDF Sumitomo Mitsui Trust | 3.27 mm | $222.80 bn |
Nikko Asset Management Americas | 3.27 mm | $222.70 bn |
Bayer Global Investments B.V. | 2.95 mm | $154.89 mm |
T. Rowe Price Investment Management | 2.70 mm | $184.33 mm |
BLK Blackrock | 2.55 mm | $173.56 bn |
FMR | 2.24 mm | $152.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jun 24 | Julianne Bruno | Common Shares | Sell | Dispose S | No | No | 56.09 | 3,366 | 188.80 k | 6,745 |
20 Jun 24 | Julianne Bruno | Common Shares | Option exercise | Acquire M | No | No | 0 | 7,000 | 0.00 | 10,111 |
20 Jun 24 | Julianne Bruno | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 7,000 | 0.00 | 0 |
30 May 24 | Sandesh Mahatme | Stock Option Common Shares | Grant | Acquire A | No | No | 54.06 | 13,000 | 702.78 k | 13,000 |
30 May 24 | Maria Fardis | Stock Option Common Shares | Grant | Acquire A | No | No | 54.06 | 13,000 | 702.78 k | 13,000 |
News
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
11 Jul 24
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
17 Jun 24
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
17 Jun 24
Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
23 May 24
CRISPR Therapeutics' Julianne Bruno, M.B.A., Promoted To COO, Effective May 23, 2024
23 May 24